Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RESET-SLE: CABA-201 in Systemic Lupus Erythematosus
NCT06121297Phase 2Recruiting
- Sponsor
- Cabaletta Bio
- Start
- Feb 2024
- Primary completion
- Dec 2029
- Countries
- 3
01
Overview
A Phase 2 trial of resecabtagene autoleucel in systemic lupus erythematosus (SLE), lupus nephritis (LN), sponsored by Cabaletta Bio. Started Feb 2024; status: recruiting.
02
Drugs
resecabtagene autoleucel
03
Conditions
systemic lupus erythematosus (SLE)lupus nephritis (LN)
Beyond the preview
Go deeper on NCT06121297.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06121297.